Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1978 Jan;38(1):18-24.

[Symptomatic therapy of primary dysmonorrhea by inhibition of prostaglandin synthesis with indomethacin (author's transl)]

[Article in German]
  • PMID: 627337
Clinical Trial

[Symptomatic therapy of primary dysmonorrhea by inhibition of prostaglandin synthesis with indomethacin (author's transl)]

[Article in German]
M Cornely et al. Geburtshilfe Frauenheilkd. 1978 Jan.

Abstract

In a controlled trial the effect of indomethacin was studied in 54 patients with primary dysmenorrhea. 34 patients were treated with 3 X 25 mg indomethacin per day orally for 5 days starting 2 days before onset of menstruation. Treatment was continued for 4 months, 20 patients received a placebo preparation. Symptoms of dysmenorrhea were reduced by 66-73% over the control group during all 4 treatment periods. 18 patients of the treated group reported complete relief from symptoms, 10 a marked improvement. Only 3 patients reported no effect of the drug, while in 3 other patients the treatment had to be discontinued due to the well-known untoward effects of indomethacin (nausea, vertigo). The therapeutic efficacy of indomethacin supports the concept of an essential role of prostaglandins in primary dysmenorrhea. The use of prostaglandin-synthetase inhibitors (aspirin-like drugs) is discussed for patient with primary dysmenorrhea who cannot be treated by contraceptive steroids.

PubMed Disclaimer